Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
José Baselga(Harvard University), John Mendelsohn(Unknown), Gabriella D’Andrea(Memorial Sloan Kettering Cancer Center), Andrew D. Seidman(Memorial Sloan Kettering Cancer Center), Barbara Burtness(Yale University), Veanne N. Anderson(Memorial Sloan Kettering Cancer Center), Larry Norton(Memorial Sloan Kettering Cancer Center), Harlan W. Waksal(Birmingham VA Medical Center), K. Gunnett(Memorial Sloan Kettering Cancer Center), Michael R. Cooper(Memorial Sloan Kettering Cancer Center), Roger B. Cohen(University of Pennsylvania), Monique M.E.M. Bos(Memorial Sloan Kettering Cancer Center), John Falcey(Memorial Sloan Kettering Cancer Center), David G. Pfister(Memorial Sloan Kettering Cancer Center)
Cited by 746
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k